Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
1999-11-12
2001-02-27
Fredman, Jeffrey (Department: 1655)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091200, C435S091400, C536S022100, C536S023100
Reexamination Certificate
active
06194158
ABSTRACT:
FIELD OF THE INVENTION
The invention relates to the field of brain cancer, in particular characteristic genes and gene expression useful in screening for, diagnosis of, monitoring of, and therapeutic treatment of cancer.
BACKGROUND OF THE INVENTION
Cancer can develop in any tissue of any organ at any age. Most cancers detected at an early stage are potentially curable; thus, physicians need a heightened awareness of predisposing inherited and environmental factors. The ability to screen patients for genetic predisposition for cancer can greatly assist in the monitoring of high-risk patients for early signs of cancer, and thus allowing for early intervention. (See for example,
The Merck Manual of Diagnosis and Therapy,
16th ed., Merck & Co., (1992)).
Malignant brain tumors (for example glioma, meningiomas, and schwannomas) are common, with an incidence of 4.5 per 100,000. The most common tumor types in adults are gliomas and meningiomas. The most common tumors in children are astrocytomas, medulloblastomas, ependymomas, and brain stem gliomas. In children, brain tumors are one of the most common causes of death from cancer. (See for example,
Professional Guide to Disease,
3rd ed., Springhouse Corp., (1989)).
Clinically, brain tumors can be characterized by their cell type and location, along with other phenotypic clues. Malignant brain tumors are sometimes catagorized as glioblastoma multiforme (spongioblastoma multiforme), astrocytoma, oligodendroglioma, ependyoma, medulloblastoma, meningioma, schwannoma, and pituitary tumors. It is also possible that cancer originating in other tissues, such as lung, liver, pancreas, colon, prostate etc., can metastasize to the brain, thus forming tumors that are not of brain origin, potentially causing confusion as to the source of cancer.
Cancer is a cellular malignancy whose unique trait—loss of normal control mechanisms—results in unregulated growth, lack of differentiation, and ability to invade local tissues and metastasize. Thus cancer cells are unlike normal cells, and are potentially identifiable by not only their phenotypic traits, but also by their biochemical and molecular biological characteristics. In particular, the altered phenotype of cancer cells indicates altered gene activity, either unusual gene expression, or gene regulation. Identification of gene expression products or proteins associated with cancer cells will allow for the molecular characterization of malignancies. The ability to specifically characterize suspected cancers, and to potentially identifiy not only cell type, but also predisposition for metastasis and any sensitivity to particular anti-cancer thereapy, is most useful for determining not only the course of treatment, but also the likelihood of success.
Thus, the discovery of specific, brain tumor characteristic gene expression is a useful and important tool useful in screening for, diagnosis of, monitoring of, and therapeutic treatment of brain cancer.
SUMMARY OF THE INVENTION
The identification of characteristic, nucleic acid signals is a useful and important discovery which allows for compositions, assays, kits and reagents suitable for the characterization of various brain cancers. Provided herein are reagents and methods for ascertaining the propensity of a cell for malignant phenotype said cell being isolated or in a biological sample, said method comprising assaying a cell or biological sample to be tested for a signal indicating the transcription of a nucleic acid transcript. In a preferred embodiment, the nucleic acids are substantially identical to the sequences of Table I, SEQ ID NOS. 1-9, and known as CINN 1, CINN 2, OP2 C2-6, OP7 C3-1, OP9 A4-2, OP11 C1-3, OP11 G2-10, FAS OP13 C1-D, FAS OP17 C1-D, dek, laminin &agr;-chain gene, &agr;-NAC gene, ribosomal protein L35a, and ribosomal protein L7a. Also provided are methods for monitoring cancer progession or the effectiveness of a treatment regimen, and methods for identifying compounds that affect expression of genes involved in cancer.
REFERENCES:
patent: 4683195 (1987-07-01), Mullis et al.
patent: 5104792 (1992-04-01), Silver et al.
patent: 5262311 (1993-11-01), Pardee et al.
patent: 5426039 (1995-06-01), Wallace et al.
patent: 5459037 (1995-10-01), Sutcliffe et al.
patent: 5556752 (1996-09-01), Lockhart et al.
patent: 5578832 (1996-11-01), Trulson et al.
patent: 5580726 (1996-12-01), Villeponteau et al.
patent: 5593839 (1997-01-01), Hubbell et al.
patent: 5599672 (1997-02-01), Liang et al.
patent: 5599695 (1997-02-01), Pease et al.
patent: 5599696 (1997-02-01), Mueller et al.
patent: 5631734 (1997-05-01), Stern et al.
patent: 5665547 (1997-09-01), Pardee et al.
patent: 5688648 (1997-11-01), Mathies et al.
patent: 5700644 (1997-12-01), Gould et al.
patent: 5710000 (1998-01-01), Sapolsky et al.
patent: 5712126 (1998-01-01), Weissman et al.
patent: 5733729 (1998-03-01), Lipshutz et al.
patent: 5744300 (1998-04-01), Linskens et al.
patent: 5744305 (1998-04-01), Fodor et al.
patent: 5744306 (1998-04-01), Murtagh, Jr. et al.
patent: 5753439 (1998-05-01), Smith et al.
patent: 5753788 (1998-05-01), Fodor et al.
patent: 5759776 (1998-06-01), Smith et al.
patent: 5770456 (1998-06-01), Holmes
patent: 5770722 (1998-06-01), Lockhart et al.
patent: 5776683 (1998-07-01), Smith et al.
patent: 5801001 (1998-09-01), Sager et al.
patent: 5807680 (1998-09-01), Sutcliffe et al.
patent: 5814445 (1998-09-01), Belyavsky et al.
patent: 5861293 (1999-01-01), Kojiri et al.
patent: 5922601 (1999-07-01), Baetscher et al.
patent: 5965409 (1999-10-01), Pardee et al.
patent: 5968784 (1999-10-01), Spinella et al.
patent: 5994076 (1999-11-01), Chenchik et al.
Der, et al., (1998),Proc. Natl. Acad. Sci. USA, vol. 95, pp. 15623-15628.
Gray, et al., (1998),Science, vol. 281, pp. 533-537.
Harkin, et al., (1999),Cell, vol. 97, pp. 575-586.
Lockhart, et al., (1969),Nature Biotechnology, vol. 14, p. 1675-1680.
Meuillet et al., (1999),Cancer Research, vol. 59, pp. 234-240.
Petretti, et al., (1999),Biochimica et Biophysica Acta, 1428:209-218.
Wang, et al., (1999),FEBS Letters, 445:269-273.
Alwine, et al., (1977),Proc. Natl. Acad. Sci.USA, 74:5350-5354.
Melton, et al., (1984),Nuc. Acids Res., 12:7035.
Berchtold, (1989),Nuc. Acids Res., 17(1):453.
Mok et al., (1994),Gynecologic Oncology, 52:247-252.
Liang and Pardee, (1992),Science, 257:967-971.
Liang, et al., (1993),Nucleic Acids Research, 21(14):3269-3275.
Wang, et al., (1996),Trends in Pharmacological Science, 17(8):276-279.
Uchiyama, et al., (1995),Neurosurgery, 37(3):464-469.
Sehgal, et al., (1997),J. of Surgical Oncology, 64:102-108.
Sehgal, et al., (1997),Int. J. Cancer, 71:565-572.
Shinoura, et al., (1995),Cancer Letters, 89:215-221.
Kito, et al., (1997),Gene, 184:73-81.
Schena, et al.,Proc. Natl. Acad. Sci. USA, Oct. 1, 1996; 93(20):10614-10619.
Heller, et al.,Proc. Natl. Acad. Sci. USA, Mar. 18, 1997; 94(6):2150-2155.
Engels et al., Angew. Chem. Int. Ed. Engl., 28:716-734 (1989).
Szer, et al.,J. Rheumatol., (1994) Nov.; 21(11):2136-2142.
Wichmann, et al.,Hum. Immunol., 1999; Jan. 60(1):57-62.
Sierakowska, et al.,Clin. Exp Immunol, 1993; Dec. 94(3):435-439.
Murray, et al.,J. Rheumatol., 1997; Mar. 24(3):560-567.
Dong, et al.,Arthritis Rheum, 1998; Aug. 41(8):1505-1510.
Arnaudo, et al.,J. Rheumatol., 1998; Sep. 25(9):1861-1862.
Patel, et al., (1994),Human Gene Therapy, 5:577-584.
Human Gene Therapy, Apr. 1994, vol. 5, pp. 543-563.
Stratford-Perricaudet, L., and M. Perricaudet, (1991), inHuman Gene Transfer, O. Cohen-Haguenauer and M. Boiron, eds., Editions John Libbey Eurotect, France, vol. 219, pp. 51-61.
Levrero, et al., (1991),Gene, 101:195-202.
Graham and Prevec, (1992), inVaccines: New Approaches to Immunological Problems, R.W. Ellis, ed., Butterworth-Heinemann, Boston, pp. 363-390.
Stratford-Perricaudet, et al., (1992),J. Clin. Invest., 90:626-630.
Rich, et al., (1993),Human Gene Ther., 4:461-476.
Crystal, et al., (1994),Nature Genetics, 8:42-51.
Rosenfeld, et al., (1992),Cell, 68:143-155.
Quantin, et al., (1992),Proc. Natl. Acad. Sci. USA, 89:2581-2584.
Herz and Gerard, (1993),Proc. Natl. Acad. Sci. USA, 90:2812-281
Kroes Roger A.
Moskal Joseph R.
Yamamoto Hirotaka
Chakrabarti Amun Kr.
Fredman Jeffrey
McDonnell & Boehnen Hulbert & Berghoff
Nyxis NeuroTherapies, Inc.
LandOfFree
Diagnostic assay for cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diagnostic assay for cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnostic assay for cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2614484